Ondine Biomedical, Inc. (GB:OBI)

LSE:OBI

OBI

Ondine Biomedical, Inc.

RESEARCH TOOLSreports

Want to see GB:OBI full AI Analyst Report?

Ondine Biomedical, Inc. (OBI) Price & Analysis

13 Followers

OBI Stock Chart & Stats

8.75 p

-0.23 p(-2.61%)

At close: Jan 09 4:00 PM EST

8.75 p

-0.23 p(-2.61%)

Day’s Range― - ―

52-Week Range7.50 p - 18.50 p

Previous CloseN/A

Volume7.12K

Average Volume (3M)160.07K

Market Cap

£67.39M

Enterprise Value114.23M

Total Cash (Recent Filing)£10.58M

Total Debt (Recent Filing)£413.50K

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Sep 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding518,366,940

10 Day Avg. Volume119,918

30 Day Avg. Volume160,072

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)21.53

Price to Sales (P/S)28.32

P/FCF Ratio-3.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)£12.20M

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthSustained top-line expansion indicates improving commercial traction and market acceptance of products, providing a structural base for future scale. If revenue growth persists, it can support operating leverage, reduce the relative size of fixed costs, and lower future financing needs.

Low Financial LeverageVery modest debt affords balance-sheet flexibility and low interest burden, which is durable during extended R&D and commercialization cycles. Low leverage reduces near-term solvency risk and gives management room to prioritize product development or absorb periodic cash burn without immediate refinancing pressure.

Specialized Infection-control TechnologyA focused, differentiated technology addressing infection prevention aligns with enduring healthcare priorities (hospital-acquired infection control). Structural demand in healthcare for infection-reduction tools can sustain long-term revenue opportunities and potential partnerships or adoption in procurement cycles.

Bears Say

Worsening Cash BurnPersistent and increasing negative operating cash flow is a structural risk: it shortens runway and forces recurrent external financing or sharp cost cuts. Over months this elevates dilution risk, constrains long-term R&D or commercialization spending, and can derail strategic initiatives if not reversed.

Sharp Gross-margin DeclineMaterial margin contraction reduces the company's ability to convert revenue into operating profit even as sales grow. This undermines operating leverage, suggests pricing, mix, or cost issues, and makes sustained profitability harder without structural fixes to cost base or product mix.

Deep Losses And Equity VolatilityVery large net losses and historical negative equity reflect chronic unprofitability and a changing capital structure. This creates ongoing dependency on external funding, increases dilution and execution risk, and can limit strategic optionality and partner confidence over the medium term.

Ondine Biomedical, Inc. News

Ondine Biomedical Expands Equity Incentives Ahead of Key FDA Milestone

Ondine Biomedical, Inc. ( ($GB:OBI) ) has issued an announcement. Ondine Biomedical has granted 3,121,471 restricted share units...

1d ago

Ondine Biomedical lifts revenue and funding as Phase 3 trial nears climax

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an update. Ondine Biomedical, a Canadian photodisinfection specialist focused on...

6d ago

Ondine Biomedical Sets Virtual 2026 AGM to Confirm Board and Auditor

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an update. Ondine Biomedical Inc. has published the notice and...

6d ago

Ondine Biomedical sets date for 2025 results and investor presentation

Ondine Biomedical, Inc. ( ($GB:OBI) ) has provided an update. Ondine Biomedical Inc., a Canadian life sciences company,...

13d ago

Ondine Highlights Feasibility Data on Nasal Photodisinfection in ICU Patients

Ondine Biomedical, Inc. ( ($GB:OBI) ) just unveiled an update. Ondine Biomedical reported that results from its SMURF...

15d ago

Light-Based Nasal Therapy Trial Completion Puts Ondine on Investors’ Radar

Ondine Biomedical, Inc. ($GB:OBI) announced an update on their ongoing clinical study. Ondine Biomedical Inc. has reported an...

28d ago

OBI

Ondine Showcases Steriwave Infection-Reduction Data at UK IPC 2026 Conference

Ondine Biomedical, Inc. ( ($GB:OBI) ) just unveiled an announcement. Ondine Biomedical, a developer of light-activated antimicrobial therapies,...

1M ago

Ondine Biomedical Raises £5 Million to Advance Steriwave Toward FDA Submission

Ondine Biomedical, Inc. ( ($GB:OBI) ) just unveiled an announcement. Ondine Biomedical has raised £5 million (C$9.23 million)...

1M ago

Ondine Biomedical launches £5m share issue to fund NDA push and extend cash runway

Ondine Biomedical, Inc. ( ($GB:OBI) ) has provided an update. Ondine Biomedical plans to raise about £5 million...

1M ago

Ondine ICU Photodisinfection Study Gains National Stage with Strong Pneumonia-Reduction Data

Ondine Biomedical, Inc. ( ($GB:OBI) ) just unveiled an announcement. Ondine Biomedical’s Steriwave nasal photodisinfection ICU study has...

1M ago

OBI FAQ

What was Ondine Biomedical, Inc.’s price range in the past 12 months?

Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 18.50 p in the past 12 months.

What is Ondine Biomedical, Inc.’s market cap?

Ondine Biomedical, Inc.’s market cap is £67.39M.

When is Ondine Biomedical, Inc.’s upcoming earnings report date?

Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 112 days.

How were Ondine Biomedical, Inc.’s earnings last quarter?

Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -0.019 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.019 p.

Is Ondine Biomedical, Inc. overvalued?

According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ondine Biomedical, Inc. pay dividends?

Ondine Biomedical, Inc. does not currently pay dividends.

What is Ondine Biomedical, Inc.’s EPS estimate?

Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ondine Biomedical, Inc. have?

Ondine Biomedical, Inc. has 518,366,940 shares outstanding.

What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?

Ondine Biomedical, Inc. reported an EPS of -0.019 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.

Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?

Currently, no hedge funds are holding shares in GB:OBI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ondine Biomedical, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-506.43%

Trailing 12-Months

Asset Growth

9.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ondine Biomedical, Inc.

Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.